Comparison of a Tissue Perfusion Guided Hemodynamic Protocol With a Standard Hemodynamic Protocol in Septic Shock Patients
NCT ID: NCT01296789
Last Updated: 2015-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
40 participants
INTERVENTIONAL
2011-02-28
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
NCT01310790
Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock
NCT02579525
Thermodilution - Controlled Management of Volume Therapy in Septic Shock
NCT01263977
Resuscitation Strategies in Septic Shock
NCT02150512
PiCCO ASSESSMENT IN PATIENTS WITH SEPTIC SHOCK
NCT05271032
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Septic shock is a frequent and severe entity with a mortality of 55%. The Surviving Sepsis Campaign (SSC) published 2008 revised guidelines to improve survival of septic shock patients.
For hemodynamic stabilization the SSC recommends as treatment goals a mean arterial blood pressure \> 65mmHg (MAP), a central venous blood pressure of 8-12 mmHg, a mixed venous oxygen saturation \>65%, a central venous oxygen saturation \> 70% and a diuresis \> 0.5 ml/kg/h (1). According to the SSC guidelines a MAP \> 65 mmHg should be aimed because at this blood pressure level tissue perfusion is preserved. This is based on a study in ten septic shock patients where norepinephrine was titrated to three levels (65, 75 and 85 mmHg) and the authors concluded that parameters of tissue perfusion did not differ between the each level (2).
Objective
To evaluate if a hemodynamic protocol guided by parameters of tissue perfusion could reduce the duration of vasopressor treatment in septic shock patients.
Methods
Patients suffering from septic shock requiring vasopressor support are randomly assigned to a control group (usual care) and an intervention group (tissue perfusion guided protocol). In the intervention group parameters of tissue perfusion are used to guide hemodynamic therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tissue perfusion guided protocol
Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
Tissue perfusion guided protocol
A tissue perfusion guided protocol is used to guide hemodynamic therapy
Usual Care
Usual Care
Usual Care
Usual Care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tissue perfusion guided protocol
A tissue perfusion guided protocol is used to guide hemodynamic therapy
Usual Care
Usual Care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented infection or strong suspicion of infection with adequate antibiotic treatment
* Shock according to ACCP/SCCM definition with the necessity of vasopressor treatment
Exclusion Criteria
* ST elevation myocardial infarction
* Pulmonary embolism
* Out of hospital cardiac arrest patients
* Patients with therapy limitations
* Known pregnancy
* Inclusion in other interventional trials
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jukka Takala
Role: STUDY_CHAIR
Department of Intensive Care Medicine, Bern University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Intensive Care Medicine, Bern University Hospital
Bern, Canton of Bern, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
101/10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.